Venatorx pharmaceuticals: new antibiotics to treat drug-resistant gram-negative bacteria including public health pathogens.
Active Definitive Contract Awarded Last action
- Contract number
- 75A50123C00050
- Awardee
-
Basilea Pharmaceutica International Ltd, Allschwil UEI UA43HWRNXFS3
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $45,192,122
Award facts
- Opportunity
-
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Pre-Solicitation · BAA18100SOL00003 · Posted Oct 16, 2017
- Contract value 24% obligated
-
- $45,192,122.00 Current, with exercised options
- $191,938,367.00 Potential, with all options
- Completion date 50% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Sharing
- Place of performance
- Malvern, PA 19355, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Funding Only Action | $5,429,906 | |
| Exercise an Option | $13,312,363 | |
| Exercise an Option | $6,128,136 | |
| Novation Agreement | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $20,321,717 |
Show all 11
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a definitive cost-sharing contract to Basilea Pharmaceutica International Ltd, Allschwil, on September 15, 2023, for new antibiotics against drug-resistant gram-negative bacteria, including public health pathogens. The contract carries a ceiling value of $191.9 million and no set-aside was used.
Performance is in Malvern, PA 19355, USA, with an ultimate completion date of December 31, 2029. The source states no base-plus-option structure. The work targets a new class of antibiotics acting on the lipopolysaccharide transport system in gram-negative bacteria and inhibitors of DXR, an essential enzyme not addressed by current antibiotics. The record reflects an administrative modification whose stated purpose is to correct IPP reporting.
The contract traces to a BARDA Broad Agency Announcement for advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats. That opportunity was posted October 16, 2017, with proposals due November 2, 2017, and a pre-proposal conference on November 7-8, 2017. The opportunity lists NAICS 541711 and 541712 and PSC codes R408 and R419. The Office of the Assistant Secretary for Preparedness and Response is the named funding agency and is civilian.
Quick answers
Who was awarded contract 75A50123C00050?
75A50123C00050 was awarded to Basilea Pharmaceutica International Ltd, Allschwil by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 15, 2023.
How much is contract 75A50123C00050 worth?
The government has obligated $45,192,122 on 75A50123C00050. Its potential value, with all options, is $191,938,367.
Was contract 75A50123C00050 competed?
The extent of competition for 75A50123C00050 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award